Lokman Hakim S, Sharifah Roohi S W, Zurkurnai Y, Noor Rain A, Mansor S M, Palmer K, Navaratnam V, Mak J W
Institute for Medical Research, Jalan Pahang, Kuala Lumpur, Malaysia.
Trans R Soc Trop Med Hyg. 1996 May-Jun;90(3):294-7. doi: 10.1016/s0035-9203(96)90258-8.
Uncomplicated falciparum malaria patients were randomly assigned to receive either 25 mg/kg chloroquine (CHL) over 3 d or a statim dose of 25 mg/kg sulfadoxine (SDX) plus 1.25 mg/kg pyrimethamine (PYR). Patients were followed up for 28 d and the parasite response graded according to World Health Organization criteria. Overall resistance to CHL was 63.3% and 47.4% to SDX/PYR. RI, RII and RIII rates were 9.1%, 42.4% and 12.1% for CHL and 10.5%, 21.1% and 15.8% for SDX/PYR, respectively. Degree and rates of resistance to CHL were significantly correlated with pre-treatment parasite density, but not those to SDX/PYR. Plasma CHL and SDX/PYR levels were within the reported ranges and were not significantly different in patients with sensitive and resistant responses.
单纯性恶性疟患者被随机分为两组，一组在3天内接受25mg/kg氯喹（CHL）治疗，另一组立即接受25mg/kg周效磺胺（SDX）加1.25mg/kg乙胺嘧啶（PYR）治疗。对患者进行了28天的随访，并根据世界卫生组织标准对寄生虫反应进行分级。对CHL的总体耐药率为63.3%，对SDX/PYR的耐药率为47.4%。CHL的RI、RII和RIII率分别为9.1%、42.4%和12.1%，SDX/PYR的RI、RII和RIII率分别为10.5%、21.1%和15.8%。对CHL的耐药程度和耐药率与治疗前的寄生虫密度显著相关，但与SDX/PYR无关。血浆CHL和SDX/PYR水平在报告范围内，敏感和耐药反应患者之间无显著差异。
